Omnicell (NASDAQ:OMCL) Issues Q2 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its second quarter earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.10-0.20 for the period, compared to the consensus estimate of $0.27. The company issued revenue guidance of $250-260 million, compared to the consensus revenue estimate of $261.84 million. Omnicell also updated its FY24 guidance to $0.90-1.40 EPS.

Wall Street Analyst Weigh In

OMCL has been the topic of a number of research reports. Wells Fargo & Company cut their price target on Omnicell from $28.00 to $26.00 and set an equal weight rating on the stock in a report on Friday, February 9th. Benchmark reaffirmed a buy rating and set a $38.00 price target on shares of Omnicell in a research report on Tuesday, April 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of Hold and a consensus price target of $42.20.

Omnicell Price Performance

Omnicell stock opened at $30.13 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.38 and a quick ratio of 2.22. Omnicell has a twelve month low of $25.69 and a twelve month high of $77.14. The company’s 50-day moving average price is $27.73 and its two-hundred day moving average price is $31.72.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 8th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. The company had revenue of $258.85 million for the quarter, compared to analysts’ expectations of $256.00 million. On average, equities research analysts predict that Omnicell will post 0.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.